Evaluating Long-term Use of a Pediatric Robotic Exoskeleton (P.REX/Agilik) to Improve Gait in Children With Movement Disorders
Launched by NATIONAL INSTITUTES OF HEALTH CLINICAL CENTER (CC) · Feb 13, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a special robotic device called an exoskeleton, which is designed to help improve walking in children aged 3 to 17 years who have movement disorders like cerebral palsy, muscular dystrophy, spina bifida, or incomplete spinal cord injury. The aim is to see if wearing this robotic device while walking can enhance their ability to walk better. To participate, children need to be able to walk at least 10 feet, have certain ranges of motion in their knees and ankles, and not have other serious health conditions that could affect their walking.
Participants in the trial will go through a few steps, starting with a physical exam and testing their walking abilities. The study is divided into three parts over a total of 36 weeks. At first, children will continue their usual therapy. Then, they will work with the robotic exoskeleton in a lab to create a custom fit and learn how to use it. Finally, they may get to take the exoskeleton home, where they’ll wear it for at least an hour each day, five days a week. Throughout the study, their walking abilities will be checked regularly to see if there are any improvements. This is an exciting opportunity for children with movement challenges to try out a new technology that may help them walk better.
Gender
ALL
Eligibility criteria
- * INCLUSION CRITERIA:
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- • Provision of signed and dated separate informed consent and assent forms for screening purposes. Upon inclusion in the protocol, provision of signed and dated informed consent and assent forms to begin participation in the study will be necessary.
- • Stated willingness to comply with all study procedures and availability for the duration of the study, or alternatively, ability to do so based on parent report and physician observation during history and physical examination.
- • Age 3 to 17 years old.
- • Have a gait pathology involving the knee joint, from a diagnosis of cerebral palsy, muscular dystrophy, spina bifida, or incomplete spinal cord injury.
- • Knee joint range of motion of at least 25 degrees in the sagittal plane (knee extension/flexion) assessed with hip extended in supine position. Hamstring contracture as assessed by straight leg raising test does not limit ability to participate in the study.
- • Ankle joint range of motion of at least 15 degrees in the sagittal plane (dorsi-plantar flexion) with the foot in neutral alignment.
- • A measured foot-thigh angle of -15 to 30 degrees in prone position.
- • Able to walk at least 10 feet without stopping with or without a walking aid.
- EXCLUSION CRITERIA:
- An individual who meets any of the following criteria will be excluded from participation in this study:
- • Any neurological, musculoskeletal or cardiorespiratory injury, health condition, or diagnosis other than cerebral palsy, muscular dystrophy, spina bifida, or incomplete spinal cord injury that would affect the ability to walk as directed with the robotic exoskeleton.
- • A history of uncontrolled seizure in the past year.
- • Pregnancy. A urine test will be performed for all participants who are able to become pregnant at the initial screening visit and in the case of a positive test, the participant will be excluded from participation. Further monitoring will rely on self-reporting of interruption in menstruation that would require re-testing for pregnancy at the next visit.
- • Any acute cardiopulmonary condition which limits exercise to less than 60 minutes per session or less than 5 days per week.
About National Institutes Of Health Clinical Center (Cc)
The National Institutes of Health Clinical Center (CC) is the nation's largest hospital dedicated exclusively to clinical research, serving as a pivotal facility for advancing medical knowledge and innovative therapies. Located in Bethesda, Maryland, the Clinical Center provides a unique environment where patients have access to cutting-edge treatments and participate in groundbreaking clinical trials across a wide range of diseases. As a leader in translational research, the CC integrates patient care with scientific investigation, fostering collaboration among researchers, clinicians, and patients to accelerate the development of new interventions and improve health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
Patients applied
Trial Officials
Thomas C Bulea, Ph.D.
Principal Investigator
National Institutes of Health Clinical Center (CC)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials